[go: up one dir, main page]

WO2023172441A3 - Trpv4 inhibitors for treating respiratory virus infections - Google Patents

Trpv4 inhibitors for treating respiratory virus infections Download PDF

Info

Publication number
WO2023172441A3
WO2023172441A3 PCT/US2023/014445 US2023014445W WO2023172441A3 WO 2023172441 A3 WO2023172441 A3 WO 2023172441A3 US 2023014445 W US2023014445 W US 2023014445W WO 2023172441 A3 WO2023172441 A3 WO 2023172441A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating respiratory
virus infections
respiratory virus
trpv4
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/014445
Other languages
French (fr)
Other versions
WO2023172441A2 (en
Inventor
Haiqing BAI
Donald E. Ingber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2023172441A2 publication Critical patent/WO2023172441A2/en
Publication of WO2023172441A3 publication Critical patent/WO2023172441A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure provides compositions and methods comprising TRPV4 inhibitors for treating respiratory viral infections, inflammatory diseases, and/or respiratory inflammation.
PCT/US2023/014445 2022-03-07 2023-03-03 Trpv4 inhibitors for treating respiratory virus infections Ceased WO2023172441A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317388P 2022-03-07 2022-03-07
US63/317,388 2022-03-07

Publications (2)

Publication Number Publication Date
WO2023172441A2 WO2023172441A2 (en) 2023-09-14
WO2023172441A3 true WO2023172441A3 (en) 2023-11-16

Family

ID=87935807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/014445 Ceased WO2023172441A2 (en) 2022-03-07 2023-03-03 Trpv4 inhibitors for treating respiratory virus infections

Country Status (1)

Country Link
WO (1) WO2023172441A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
US20180235931A1 (en) * 2017-01-17 2018-08-23 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists as antitussives
US20190091206A1 (en) * 2016-04-07 2019-03-28 Duke University Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing
US20210145937A1 (en) * 2017-06-19 2021-05-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
US20190091206A1 (en) * 2016-04-07 2019-03-28 Duke University Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing
US20180235931A1 (en) * 2017-01-17 2018-08-23 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists as antitussives
US20210145937A1 (en) * 2017-06-19 2021-05-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABDELMOATY SALLY, WIGERBLAD GUSTAF, BAS DUYGU B., CODELUPPI SIMONE, FERNANDEZ-ZAFRA TERESA, EL-AWADY EL-SAYED, MOUSTAFA YASSER, AB: "Spinal Actions of Lipoxin A4 and 17(R)-Resolvin D1 Attenuate Inflammation-Induced Mechanical Hypersensitivity and Spinal TNF Release", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 8, no. 9, US , pages e75543, XP093112277, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0075543 *
CLARK D. RUSSELL; JÜRGEN SCHWARZE: "The role of pro‐resolution lipid mediators in infectious disease", CANCER RESEARCH, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 141, no. 2, 9 January 2014 (2014-01-09), GB , pages 166 - 173, XP071276686, ISSN: 0019-2805, DOI: 10.1111/imm.12206 *
KUEBLER WOLFGANG M., JORDT SVEN-ERIC, LIEDTKE WOLFGANG B.: "Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 318, no. 6, 1 June 2020 (2020-06-01), US , pages 1239 - 1243, XP093112280, ISSN: 1040-0605, DOI: 10.1152/ajplung.00161.2020 *

Also Published As

Publication number Publication date
WO2023172441A2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2023012981A (en) Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use.
AU2020342649B2 (en) Compositions and methods for the treatment of viral infections
CL2021002878A1 (en) Treatment and prevention of metabolic diseases
WO2020171727A3 (en) Mucoadhesive compositions and uses thereof
EP4596048A3 (en) Cd73 inhibitors
PH12021553180A1 (en) Inhibitors of human immunodeficiency virus replication
MX2024010591A (en) Compounds and methods for treatment of viral infections.
PH12021551451A1 (en) Combination hbv therapy
EP4389209A3 (en) Fecal microbiota composition, for use in reducing treatment-induced inflammation
MX2020010697A (en) Kit, composition and combination therapy for fragile x syndrome.
PH12022550130A1 (en) Enzyme inhibitors
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2021013602A (en) JAK INHIBITORS.
EP4213820A4 (en) Methods and compositions for treating viral infections
WO2024099364A3 (en) Fused multicyclic compounds and their use as parp1 inhibitors
PH12022550846A1 (en) Thienopyrimidones as trpa1 inhibitors
WO2023122260A3 (en) Inhibitors of sars-cov-2
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
ZA202106519B (en) Caspase inhibitors and methods of use thereof
WO2023172441A3 (en) Trpv4 inhibitors for treating respiratory virus infections
WO2022063869A3 (en) Compounds for the treatment of viral infections
WO2021118924A3 (en) Compositions and methods for the prevention and treatment of hearing loss
WO2023003951A3 (en) Compositions and methods for the treatment of herpes simplex virus infection
CR20240365A (en) Antiviral compounds and methods of making and using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23767323

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23767323

Country of ref document: EP

Kind code of ref document: A2